Meridian Valley LAB
6839 Fort Dent Way, Ste 206
Tukwila, WA 98188
tel 206.209.4200 • 855.405.TEST (8378)
fax 206.209.4211

Accession #:
Patient Name:
Date of Birth:
Age: Gender:
Collected:
Received:
Reported:
Tech:

Test: **4996**

Doctor ID:

Phone:
Fax:

DU Sex Hormone Profile

Comments:

Creatinine: 75 mg/dL

Estrogens

	µg/g Creatinine		Luteal	Post-Menopausal
			Reference Ranges	
			Postmenopausal women on hormones, or cycling women collecting during the luteal phase, refer to the luteal reference range.	Postmenopausal women not taking hormones, refer to the post-menopausal reference range
Estrone (E1)	**2.3**		4.1 – 21.6	0.7 – 5.2
Estradiol (E2)	**0.8**		1.6 – 6.6	0 – 2.8
Estriol (E3)	**1.1**		5.4 – 23.2	0 – 5.7
Total (E1 + E2 + E3)	**4.2**		12.6 – 47.8	0 – 13.6
Phase I Metabolites				
2-OH Estrone (2OHE1)	**5.3**		3.2 – 22.2	0.2 – 4.1
16α-OH Estrone (16αOHE1)	**0.3**		1.2 – 7.1	0.1 – 2.4
4-OH Estrone (4OHE1)	**0.76**		0.32 – 2.26	0 – 0.82
2/16 Ratio	**15.2**	**H**	1.6 – 7.7	1.6 – 7.7
Phase II Metabolites				
2-Methoxyestrone	**1.06**		1 – 6.8	0.2 – 2.3
2-Methoxyestradiol	**0.10**		0.1 – 0.53	0 – 0.22

Other Reference Ranges	Estrone	Estradiol	Estriol	Estrogen Total	Pregnanediol
Follicular	2.0-39	1.0-23	3.0-48	7.0-110	0-2500
Mid-Cycle	11.0-46	4.0-45	20-130	38-221	N/A

DU Sex Hormone Profile

Accession #: Test Code: **4996**

Patient Name:

Estrogen Ratios

Estrogen Ratios

Estrogen Quotient: 0.3

E3/(E1+E2)

Patient Result



Reference Range

>1



Patients with an EQ>1 have a higher survival rate after breast cancer, and may be at decreased risk for developing breast cancer. EQ often declines as women enter menopause.

Estrogen Hydroxylation

Patient Result



Reference Range



2-OHE1, a Phase I liver metabolite of estrone, is considered protective. 16α-OHE1 is a Phase I metabolite of estrone that has some duality: it is potentially carcinogenic and it is important for building bone. Therefore, very high levels and very low levels are both undesireable. High levels suggest a need for measures to improve estrogen detoxification. Low levels may increase risk of osteopenia.

4-OHE1 is a highly carcinogenic Phase I metabolite. Low levels are desireable.

Methylation Ratio: 0.20

2-Methoxyestrone/2OHE1

Patient Result

Reference Range

0.2 - 0.65

A comparison of 2-Methoxyestrone with 2OHE1 allows insight into methylation pathways. If the methylation ratio is on the low end of the reference range, consider adding supplements to improve methylation. If needed, consider further testing for methylation defects.

Progesterone

	µg/g Creatinine	Reference Ranges
5β-Pregnanediol	**288**	Luteal: 689 – 3871; Post-Menopausal: 167 – 537
Pregnanetriol	**149**	140 – 1293

DU Sex Hormone Profile

Accession #: Test Code: **4996**

Patient Name:

Androgens

	µg/g Creatinine		Reference Range
DHEA	**718**		100 – 1333
Androsterone	**587**	**L**	636 – 2327
Etiocholanolone	**524**	**L**	630 – 3006
Testosterone	**< 0.3**	**L**	3 – 12.2
DHT	**< 0.3**		0.3 – 2.9
5α-Androstanediol	**8.5**		4 – 33
5β-Androstanediol	**10.9**		8 – 122

Enzyme Activity Phenotype Assessment

		Reference Range
5α-Reductase		
Andro/Etio Ratio	**1.12**	0.6 – 2.2

Elevated 5α-reductase activity is associated with Polycystic Ovarian Syndrome (PCOS) and hirsutism in women, Benign Prostatic Hyperplasia (BPH) and premature baldness in men, and obesity and insulin resistance in both genders. Low 5α-reductase activity may result in reduced conversion of testosterone to DHT and undervirilization in males.